ATLANTA, June 11, 2025 — Femasys Inc. (Nasdaq: FEMY), a leader in women’s reproductive health innovation, has announced a new partnership with Carolinas Fertility Institute (CFI), a top-rated fertility clinic network. This collaboration will make the company’s advanced fertility product, FemaSeed®, available across CFI’s eight locations in North Carolina.
FemaSeed is designed to offer a less invasive, more affordable alternative to in vitro fertilization (IVF). It precisely delivers sperm directly into the fallopian tube, enhancing the chances of natural conception. This next-generation technology is now part of CFI’s range of treatment options for patients trying to conceive.
A New Path Forward in Fertility Care
Kathy Lee-Sepsick, CEO and Founder of Femasys, emphasized the importance of the partnership.
“Working with CFI highlights the growing demand for FemaSeed as a practical, early-stage fertility option,” said Lee-Sepsick. “We aim to help clinics broaden their services and support patients sooner in their fertility journey by providing a cost-effective and less invasive alternative to IVF.”
Dr. Tamer Yalcinkaya, Founder and Medical Director of Carolinas Fertility Institute, echoed this sentiment.
“At CFI, we’re always seeking ways to offer innovative, patient-friendly fertility solutions,” he said. “FemaSeed fits perfectly into our mission to provide cutting-edge care that’s both affordable and accessible.”
What Is FemaSeed?
FemaSeed® Intratubal Insemination is an advanced artificial insemination treatment. It increases fertilization rates by directly delivering sperm to the fallopian tube — the natural site of conception. It is especially effective for couples facing male infertility issues, such as low sperm count.
In clinical studies, FemaSeed showed more than double the pregnancy success rates compared to traditional intrauterine insemination (IUI), without increased risks. The product is FDA-authorized in the U.S. and is also approved for use in Europe, the UK, Canada, and Israel.
About Femasys
Femasys is a U.S.-based biomedical company focused on unmet needs in women’s reproductive health. It offers a suite of accessible, in-office products designed to treat and diagnose fertility and other conditions.
Its fertility solutions include:
FemaSeed®, an innovative insemination option,
FemVue®, a diagnostic tool for evaluating fallopian tube health,
FemBloc®, a non-surgical permanent birth control method currently undergoing regulatory review in Europe.
FemBloc, if approved, will be the first non-surgical sterilization method available in-office. Commercial rollout is planned to start in Spain and expand to other European countries. The U.S. approval process is ongoing, with patient enrollment continuing in a pivotal clinical trial.
About Carolinas Fertility Institute
Carolinas Fertility Institute serves patients across North Carolina through clinics in Winston-Salem, Greensboro, and Charlotte. Led by experienced reproductive endocrinologists, CFI provides personalized fertility care, including IVF, IUI, fertility preservation, and diagnostics.
CFI is committed to making high-quality fertility care more accessible. Their approach blends advanced medical techniques with compassion and affordability, aiming to help more families realize their dream of parenthood.
For more information on the FemaSeed treatment, visit www.femaseed.com. To learn about Carolinas Fertility Institute, visit www.carolinasfertilityinstitute.com.
Forward-Looking Statement Notice
This article includes forward-looking statements regarding Femasys’ products and partnerships. These statements involve risks and uncertainties that may cause actual outcomes to differ significantly from what is expected. For more details, readers should consult the company’s filings with the U.S. Securities and Exchange Commission.
Related topics:
